Latigo Biotherapeutics, Inc. (LTGO) Stock Forecast
LTGO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $52.25 average of analyst targets
- Upside to target
- +273.2% from the latest close
- Next earnings
- December 3, 2026
- 52-week range
- $14.00 – $25.00
LTGO analyst ratings
4 analystsNumber of analysts at each rating.
LTGO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LTGO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.67 | −$0.69 | −$0.65 | — | — | 2 |
| Current fiscal year (2026) | −$3.01 | −$4.52 | −$2.11 | −$129.26 | +97.7% | 3 |
| Next fiscal year (2027) | −$2.32 | −$2.76 | −$2.07 | −$3.01 | +23.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LTGO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
LTGO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LTGO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$0.67 | −$0.67 | −$0.67 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | −$3.01 | −$3.01 | −$3.01 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | −$2.32 | −$2.32 | −$2.32 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LTGO earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; LTGO beat in 0 of 1.
What analysts expect from LTGO
4 analysts cover Latigo Biotherapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $52.25, 273.2% above the latest close of $14.00. Analysts expect earnings of −$3.01 per share for 2026, +97.7% from a year earlier. For 2027 the average estimate is −$2.32 per share. Latigo Biotherapeutics beat the EPS estimate in 0 of the last 1 quarters.
Related: LTGO income statement, LTGO key metrics, LTGO chart. See the LTGO stock overview for the latest quote and news.
LTGO forecast FAQ
What is Latigo Biotherapeutics's price target?
The average analyst price target for Latigo Biotherapeutics is $52.25, 273.2% above the latest close of $14.00.
Is Latigo Biotherapeutics a buy, hold or sell?
Of 4 analysts covering Latigo Biotherapeutics, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Latigo Biotherapeutics's EPS forecast?
Analysts forecast −$3.01 per share for 2026 (range −$4.52 to −$2.11); for 2027 the estimate is −$2.32.
When does Latigo Biotherapeutics report earnings?
Latigo Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on December 3, 2026.
Does Latigo Biotherapeutics usually beat earnings estimates?
Latigo Biotherapeutics reported EPS at or above the analyst estimate in 0 of the last 1 quarters.